Population pharmacokinetic analysis of sorafenib in patients with solid tumours. - Wikidata - awgldk - TriplyDB

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

http://www.wikidata.org/entity/Q35183640

about

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.Sorafenib in advanced melanoma: a critical role for pharmacokinetics?Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.Methodological assessment of HCC literature A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma.Population pharmacokinetic analysis of axitinib in healthy volunteers.Patient-Level Adverse Event Patterns in a Single-Institution Study of the Multi-Kinase Inhibitor Sorafenib.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors.PharmGKB summary: sorafenib pathways.Sorafenib-Induced Acute Pancreatitis: Case Report and Review of the Literature.Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.Commentary on: "Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide".Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Pharmacokinetics of single-agent axitinib across multiple solid tumor types.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS- Mutant Cancers.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients.Molecular Dynamics Simulation of VEGFR2 with Sorafenib and Other Urea-Substituted Aryloxy Compounds

P2860

Q28482219-8D0366B6-F829-4D79-A780-25B7E14AAD70 Q30587082-9CBC1F04-CAD7-408C-9C53-EDA1889DB220 Q33411001-79203D9A-B0EF-473E-B5FB-44D73CB398CC Q33891564-748F8ADA-6077-4642-905A-8274765A1E41 Q35812091-1C86DCF7-7339-41FF-887D-924DAEF2CC68 Q36117220-837D0DE1-7BCD-45BC-8CA4-056FCE1363C3 Q36125978-7CA93F4D-C8A1-42F1-B0E3-D65FD1ED67A1 Q36698681-B7C475B6-8CA9-4285-9EFA-67EBA1C4C839 Q36837652-2608A39B-5454-447A-8FA6-F102AB9FEB6A Q36910794-C6CDD509-A12F-4EF9-A04C-AFF67016BBAA Q36963820-54E2645A-F830-4BB2-82F8-0D7906FA7356 Q37354482-27A4B8EE-A3BB-4B8A-AA65-74CACE8432FE Q37404382-FADD8B7B-5637-4ABE-A6AA-A5656CD2EDE0 Q37536010-686D0BCB-375D-49C4-B54B-243CB3782318 Q37635202-5E294245-C4BD-4490-9739-4016DA5D41CB Q37700647-ACD7AB64-3639-4223-9387-DAEE6A32E4B2 Q38190857-57F01E67-35DA-460A-BF95-EB7190B77F19 Q38292288-194C71D7-8942-477E-B161-72B32483B820 Q38838740-6913AA5A-42A9-440A-9429-4A77A711D693 Q38864682-D7021A08-90A0-4218-917F-33B6490D3F93 Q39406283-2059B690-7657-4D43-9373-FBAB0A6A6EB2 Q40670954-03637225-5054-49C3-A969-64C97BB96C70 Q40914650-353117E3-CED5-4AC7-A5E0-7772083CFEB8 Q40976710-8AE4D121-B0D2-4617-B292-A838176A54F0 Q42575030-5D6582D2-5DA4-4440-8C74-F1F93A3152C6 Q43841175-38E8B1C1-65EE-4C47-9166-C54AF96F525C Q44982199-FBB08985-D854-4C17-847A-A9EE394961BF Q47969048-76FD4656-9216-499C-B253-9F1A3C2BB475 Q48583910-FC0E05E6-D887-4A8B-A1D9-405AC69E0ADA Q50091855-6A05D6F4-AEE8-4E3C-BE1C-2423368AA141 Q51007060-3E096D0C-D02F-4789-BFBE-4AF6989E732B Q51099990-3266C3F3-1DFA-42F4-93C8-BF17E6832766 Q54113908-1E8022D9-F215-47AA-99C9-1C9E42058C8A Q54313392-14B08329-49D7-481E-9ADC-2C7B12B886A2 Q59022306-70D0F7B8-78D9-4FBD-91D8-019854341908

P2860

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

http://www.wikidata.org/entity/Q35183640

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

@ast

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

@en

type

label

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

@ast

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

@en

prefLabel

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

@ast

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

@en

P1433

Q35183640-7746C95A-2B07-41ED-8973-62E205AD245A

P1476

Q35183640-C3343E12-19BB-424F-AE89-A320D2A948A3

P2093

Q35183640-1B85CAA3-0331-48BE-9BA5-0D94A8463B3E

Q35183640-398D0AB7-6E14-427C-A2FC-A267DE3F5493

Q35183640-3D6BA877-B698-4C92-93C8-F874516AA17F

Q35183640-6B0042FF-DC8E-4AAE-8C60-5A49F59DF7D5

Q35183640-7E98C36F-7AFF-4B72-A651-ACE42CE00399

Q35183640-88AAB5AF-117F-48D4-89A4-377673DB0DB3

Q35183640-950B6EF4-F4C9-4DAE-AA72-0D27B9138418

Q35183640-E255FABF-895C-4592-8B5C-DF622CCFA836

Q35183640-E4DDAC52-C445-4ECF-98A0-33AE4FFA925C

Q35183640-FF593DB6-5E20-4CE1-BCD3-D742C66178BD

P2860

Q35183640-0F0A8D4C-F746-4386-BA60-C2002FF8FF42

Q35183640-166A6103-4AC7-4F66-8312-0CFDFE3396F2

Q35183640-3B158384-76EB-4AB1-8B7F-DB34ABDEECF3

Q35183640-45C34287-0539-4C7E-8BB9-BB3AC8703AB0

Q35183640-484CAF6A-A054-4422-AECE-7E02C1343F24

Q35183640-55193322-E613-4BB9-90FB-88E09D14DF7F

Q35183640-559311A0-9837-4759-93B9-E83E25CF5631

Q35183640-5EB72029-BCFA-4F00-8D8F-078A247171E1

Q35183640-69B6132E-1C5D-43AA-9528-9A16B90A7B6B

Q35183640-7A43E9E0-0C5A-43FE-8A09-085C2FA1A799

P304

Q35183640-F49E26BB-BB61-418B-BCD8-BD28BED0D7D0

P31

Q35183640-A005807C-3A92-4307-8FA9-DFD7563DD5D4

P356

Q35183640-9F67DD2D-D023-4E50-B9FD-16B06FC9FE24

P407

Q35183640-DF05DA7A-001D-453D-994C-8C4A6AE333AE

P433

Q35183640-8954F507-DDD1-4F50-AFFB-D7F3958E003E

P478

Q35183640-FCEA4057-D017-4D58-826E-2ED277FBE2D1

P50

Q35183640-6F687ECA-4DA6-4169-8C64-39057E5FACE9

P577

Q35183640-EE99CA11-369E-4B17-9617-126FCACCA35D

P5875

Q35183640-EAABD492-EE61-4D36-834A-108D2EF96115

P698

Q35183640-5AC9A1EB-6835-48BE-B52E-B0B9359ED1A0

P932

Q35183640-EE721489-E393-42EF-AC80-67CBA6E4F64A

P356

J.1365-2125.2011.03963.X

P1433

British Journal of Clinical Pharmacology

P1476

Population pharmacokinetic analysis of sorafenib in patients with solid tumours

@en

P2093

Diane R Mould

http://www.w3.org/2001/XMLSchema#string

Elise C Kohn

http://www.w3.org/2001/XMLSchema#string

Erin R Gardner

http://www.w3.org/2001/XMLSchema#string

Jürgen Venitz

http://www.w3.org/2001/XMLSchema#string

Lokesh Jain

http://www.w3.org/2001/XMLSchema#string

Robert Yarchoan

http://www.w3.org/2001/XMLSchema#string

Shivaani Kummar

http://www.w3.org/2001/XMLSchema#string

Sukyung Woo

http://www.w3.org/2001/XMLSchema#string

William D Figg

http://www.w3.org/2001/XMLSchema#string

William L Dahut

http://www.w3.org/2001/XMLSchema#string

P2860

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

A general model for the origin of allometric scaling laws in biology

cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450

Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.

Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.

Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

P304

294-305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2011.03963.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Giaccone

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50362474

http://www.w3.org/2001/XMLSchema#string

P698

21392074

http://www.w3.org/2001/XMLSchema#string

P932

3162659

http://www.w3.org/2001/XMLSchema#string